Global Health Agencies and Vaccine-Preventable Deaths Debate

Full Debate: Read Full Debate
Department: Foreign, Commonwealth & Development Office

Global Health Agencies and Vaccine-Preventable Deaths

Virendra Sharma Excerpts
Thursday 9th May 2024

(7 months, 1 week ago)

Westminster Hall
Read Full debate Read Hansard Text Read Debate Ministerial Extracts

Westminster Hall is an alternative Chamber for MPs to hold debates, named after the adjoining Westminster Hall.

Each debate is chaired by an MP from the Panel of Chairs, rather than the Speaker or Deputy Speaker. A Government Minister will give the final speech, and no votes may be called on the debate topic.

This information is provided by Parallel Parliament and does not comprise part of the offical record

Virendra Sharma Portrait Mr Virendra Sharma (Ealing, Southall) (Lab)
- Hansard - -

I beg to move,

That this House has considered global health agencies and vaccine-preventable deaths.

It is a pleasure to serve under your chairmanship, Sir Gary. I thank the Backbench Business Committee for granting me time today to speak about the importance of vaccines and immunisation in tackling humanity’s greatest and deadliest diseases.

The discovery and development of vaccinations is one of the most significant and impactful achievements in human history. It was here in the UK that Edward Jenner first isolated cowpox to create the world’s first vaccine: the smallpox vaccine. Since that incredible scientific breakthrough, researchers across the world have worked on developing inoculating vaccines to combat all manner of infectious diseases, including polio, influenza, diphtheria, and of course tuberculosis. As the co-chair of the all-party parliamentary group on global tuberculosis, that cause is particularly close to my heart.

Vaccines are a vital part of our public health infrastructure. First and arguably most important, vaccines help to prevent the spread of diseases by supporting the body’s immune system to fight off infections. It is irrefutable that vaccines have a positive effect in reducing the incidence, spread and mortality of infectious diseases and that when a significant proportion of the population is vaccinated, herd immunity develops, which provides indirect protection for marginal and at-risk groups, including children, the elderly and those with pre-existing medical conditions. Vaccines not only help to eradicate disease, but significantly improve the quality of life of the population by protecting against further illnesses that can lead to long-term or chronic health problems.

History has shown us how effective vaccines are. Polio was one of the leading causes of death across the world in the 20th century. Since the global polio eradication initiative began in 1988, polio cases worldwide have decreased by a staggering 99%, and many countries, such as India, have been declared polio-free as a result of our efforts. That has been achieved only because of the ambitious vaccination programme. Measles used to kill approximately 2.5 million people each year, yet since the introduction of a vaccine, more than 23 million lives have been saved. More recently, the human papillomavirus vaccine, which is used to combat cervical cancer, has been shown to reduce incidence of cancer by 40%. The history of vaccination shows us all that vaccines work, they are safe, and they are the most effective way of preventing infectious diseases.

Last week, we celebrated World Immunisation Week. This annual event, led by the World Health Organisation, aims to mobilise the international community to overcome the barriers to vaccine coverage. I was pleased to join colleagues from across the House and across the global health landscape at last week’s brilliant event on World Immunisation Week, hosted by the APPG on vaccinations for all. At the reception we heard from representatives from Gavi, the Vaccine Alliance. Gavi is a multilateral health organisation founded in 2000 that vaccinates over 50% of the children on the planet against infectious and deadly diseases. Through numerous health emergencies, Gavi’s innovation has underpinned a track record of success. It is now supporting promising vaccine candidates for malaria, TB and HIV.

The UK Government have a strong record of supporting Gavi, both with research and development, and with the roll-out of new vaccines. Gavi’s work aligns closely with the Government’s priority to end the preventable deaths of mothers and children. As I am sure the Minister is aware, Gavi is currently beginning to plan for its next replenishment, where countries around the world will commit financial resources to support Gavi’s mission. I ask the Minister: how has the Foreign, Commonwealth and Development Office been engaging with Gavi in the lead-up to the replenishment, and can he give an assurance that the UK will remain one of the leading global supporters of Gavi’s mission?

Gavi is not the only development organisation that plays a leading role in vaccinating people in high-risk or conflict-affected areas. The Global Fund, established under a Labour Government in 2002, has a long and accomplished history of tackling the TB, malaria and HIV epidemics, helping to save nearly 60 million lives since its inception. The Global Fund is the world’s largest multilateral provider of grants for strengthening health systems, investing $1.5 billion a year from 2021 to 2023.

In many countries, the Global Fund works in partnership with Gavi to support the successful roll-out of immunisation across health systems. That is because we know that having strong, responsive and accountable local health systems is imperative to tackling novel and legacy infectious disease. Without a strong health system, cases of infection go unrecorded, symptoms go untreated, diseases spread and untimely deaths increase. I ask the Minister: what support the Government are giving to the Global Fund to support its mission of strengthening health systems around the world?

The success of the mRNA vaccine during the covid-19 pandemic has led to the development of a number of promising vaccine candidates that should start to be rolled out in the near future. One such vaccine is for malaria, which is one of the world’s deadliest diseases, killing a child almost every minute. In the last few years, the World Health Organisation has granted conditional approval to two malaria vaccines, with Cameroon being the first country in the world to receive them. I know that colleagues across the House will be fascinated to see the impact that the new malaria vaccine has. We all hope that the two new vaccines are a stepping stone to more innovative and effective tools and medicines that can be used to eradicate the disease for good.

We cannot, however, be complacent. Research shows that vaccines in isolation are not enough. Vaccine programmes must be accompanied by other effective public health measures, such as population screening, case finding, education programmes and robust health systems. Strong health systems are fundamental to a successful vaccine roll-out. Particular attention should be paid to healthcare worker training, supply chain management and facilities capable of delivering vaccines safely.

In addition, local manufacturing capabilities need to be strengthened so that vaccines can be produced anywhere in the world at a much quicker pace. We saw the limitations of a lack of local manufacturing during the covid-19 pandemic, when many countries in the global south were the last to receive covid vaccines, after many people in the global north had already received multiple jabs. The inequality in our vaccine manufacturing capabilities has cost lives before, and we must ensure it never happens again. Will the Minister say what the FCDO is doing to support countries around the world to develop their own vaccine manufacturing capabilities, so that they can respond more quickly to future global health emergencies?

I am thankful for the timely opportunity to raise this vital issue with the House. The UK has always played a leading role in the research, development and financing of vaccinations; it is a legacy of which we can be proud, but we must not rest on our laurels, as the last few years have shown us that global health emergencies can arise at any time, anywhere, with untold consequences. I hope the Government will continue to strongly support organisations such as Gavi and the Global Fund in their efforts to vaccinate and eradicate disease worldwide. I fully expect that when the Global Fund and Gavi host their respective replenishment conferences next year, the UK Government will generously pledge significant financial support to both. Perhaps the Minister can confirm today that this will be the case.

Gary Streeter Portrait Sir Gary Streeter (in the Chair)
- Hansard - - - Excerpts

Before I turn to the SNP spokesman, can I check whether the Father of the House wishes to speak in the debate?

--- Later in debate ---
Virendra Sharma Portrait Mr Sharma
- Hansard - -

I am grateful for the opportunity to hold this debate, which has addressed many issues. I thank the Front Benchers for their support and their contributions. In particular, I thank the Father of the House for his presence and his intervention on the Minister.

I also thank the Minister for his response. This is a matter very close to both our hearts, and is very important to all those present and to people outside the Chamber. Thank you, Sir Gary, for the opportunity to serve under your chairmanship. I thank everybody present.

Question put and agreed to.

Resolved,

That this House has considered global health agencies and vaccine-preventable deaths.